Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon

Leukemia Research

Volumn 31, Issue 8, 2007, Pages 1153-1155

  Ali, Ridvan ^a   Ozkalemkas, Fahir ^a   Ozkan, Atilla ^a   Ozkocaman, Vildan ^a   Ozcelik, Tulay ^a   Ozan, Ulku ^a   Kurt, Meral ^a   Tunali, Ahmet ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BONE MARROW BIOPSY; CANCER RELAPSE; CANCER STAGING; CASE REPORT; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PLASMACYTOMA; PNEUMONIA; PRIORITY JOURNAL; RADIODIAGNOSIS; REMISSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; MULTIPLE MYELOMA; PLASMACYTOMA; PYRAZINES; TREATMENT OUTCOME;

EID: 34249871670     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.07.017     Document Type: Letter

References (9)

1. Nolan K.D., Mone M.C., and Nelson E.W. Plasma cell neoplasms. Review of disease progression and report of a new variant. Surg Oncol 14 (2005) 85-90
2. Rosinol L., Cibeira M.T., Blade J., Esteve J., Aymerich M., Rozman M., et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 89 (2004) 832-836
3. Terpos E., Rezvani K., Basu S., Milne A.E., Rose P.E., Scott G.L., et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 75 (2005) 376-383
4. San Miguel J., Blade J., Boccadoro M., Cavenagh J., Glasmacher A., Jagannath S., et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11 (2006) 51-61
5. Patriarca F., Prosdocimo S., Tomadini V., Vasciaveo A., Bruno B., and Fanin R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 90 (2005) 278-279
6. Pantelidou D., Tsatalas C., Margaritis D., Anastasiadis A.G., Kaloutsi V., Argyropoulou P., et al. Successful treatment of lymph node extramedullary plasmacytoma with bortezomib. Ann Hematol 85 (2006) 188-190
7. Rosinol L., Cibeira M.T., Uriburu C., Yantorno S., Salamero O., Blade J., et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76 (2006) 405-408
8. Ali R., Ozkalemkas F., Ozcelik T., Ozkan A., Ozkocaman V., Ozturk H., et al. Extramedullary plasmacytoma involving the abdominal vessels and pancreas. Dig Dis Sci (2006) 10.1007/s10620-005-9044-6
9. Anagnostopoulos A., Hamilos G., Zorzou M.P., Grikoraki V., Anagnostou D., and Dimopoulos M.A. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Leuk Lymphoma 45 (2004) 113-116